There is no published evidence that a transdermal patch delivers a clinically meaningful dose of a GLP-1 receptor agonist. Every GLP-1 medicine with trial evidence behind it, such as semaglutide and tirzepatide, is given by injection or, in one case, as a specially formulated oral tablet. The patches marketed online are generally not the same class of product, and most do not contain a real GLP-1 drug at all.
Reviewed for accuracy · Last reviewed July 8, 2026GLP-1 receptor agonists are peptides, which are chains of amino acids. Peptides are large, water-loving molecules that do not cross intact skin easily and are readily broken down by enzymes. That is the practical reason the approved products are injected: an injection places the peptide directly under the skin where it can be absorbed reliably.
Oral semaglutide exists, but it only works because it is co-formulated with an absorption enhancer and taken under strict fasting conditions, and even then only a small fraction is absorbed. A passive skin patch has none of that engineering, so the burden of proof is on any patch claiming to deliver a working GLP-1 dose.
Many products marketed as GLP-1 patches are supplement patches. Rather than a GLP-1 drug, they tend to contain ingredients such as berberine, chromium, or plant extracts that are described as supporting GLP-1 activity indirectly. That is a very different claim from delivering the drug itself, and the marketing often blurs the two.
Because these are sold as supplements rather than approved medicines, they are not held to the same evidence standard, and there are no controlled trials showing that the patch form produces the weight or blood-sugar effects seen with injectable GLP-1 drugs.